Search Result

Results for "

G 12

" in MedChemExpress (MCE) Product Catalog:

By Targets:	AMPK (1) Apoptosis (11) Bcl-2 Family (1) Bombesin Receptor (1) E3 Ligase Ligand-Linker Conjugates (1) ERK (5) HIV (1) IFNAR (1) Interleukin Related (1) Isotope-Labeled Compounds (1) JNK (1) MEK (1) mTOR (1) p38 MAPK (1) PARP (1) PERK (3) Phosphatase (1) PI3K (1) PKA (2) PROTACs (7) Protease Activated Receptor (PAR) (1) Raf (2) Ras (191) Ribosomal S6 Kinase (RSK) (1) Small Interfering RNA (siRNA) (2) Target Protein Ligand-Linker Conjugates (1) ULK (1) Wnt (1) YAP (1)
By Research Areas:	Cancer (210) Infection (1) Inflammation/Immunology (6) Metabolic Disease (2)
Click Chemistry:	Azide (3) Alkynes (16)
Oligonucleotides:	Pre-designed siRNA Sets (2) siRNAs (2)

212

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

*KRAS G12D inhibitor 14*	Ras Apoptosis	Cancer
KRAS G12D inhibitor 14 is a potent KRAS G12D inhibitor with a K_D of 33 nM for binding to KRAS G12D protein. KRAS G12D inhibitor 14 decreases the active form of KRAS G12D (KRAS G12D-GTP) but not KRAS G13D .

*K-Ras G12C-IN-3*	Ras	Cancer
K-Ras G12C-IN-3 is a novel and irreversible inhibitor of mutant K-ras G12C.

*PROTAC KRAS G12C degrader-1*	PROTACs	Cancer
PROTAC KRAS G12C degrader-1 is a Cereblon-based KRAS ^G12C PROTAC degrader. PROTAC KRAS G12C degrader-1 induces CRBN/ KRAS ^G12C dimerization and degrades GFP- KRAS ^G12C in reporter cells .

*K-Ras G12C-IN-4*	Ras	Cancer
K-Ras G12C-IN-4, compound 1, is a potent Covalent Inhibitor of KRAS ^G12C .

G12Si-2	Ras	Cancer
G12Si-2, an analog of G12Si-1 (HY-150926), is a negative control tool. G12Si-2 is not a covalent inhibitor of the G12S mutant of K-Ras .

G12Si-1	Ras	Cancer
G12Si-1 is a selective *K-Ras(G12S)* covalent inhibitor, which can inhibit oncogenic signaling of *K-Ras(G12S). G12Si-1 shows good ability to covalently engage recombinant K-Ras(G12S)* at the mutant serine residue. G12Si-1 can also affect nucleotide cycling of K-Ras by blocking Sos-catalyzed exchange and decreasing the rate of EDTA promoted exchange .

*(R)-G12Di-7*	Ras	Cancer
(R)-G12Di-7 is a covalent ligand for *KRAS-G12D, which selectively labels K-Ras-G12D·GDP and K-Ras-G12D·GppNHp. (R)-G12Di-7 exhibits inhibitory activity against G12*D mutated cancer cells .

*KRAS G12D modulator-1*	Ras	Cancer
KRAS G12D modulator-1 (compound 6) is a potent KRAS G12D modulator with IC₅₀ values of 1-10 μM for NEA-G12D, PPI-G12D, and p ERK-AGS, respectively. KRAS G12D modulator-1 can be used in research of cancer .

*K-Ras G12C-IN-2*	Ras	Cancer
K-Ras G12C-IN-2 is an irreversible covalent K-Ras G12C inhibitor.

*(RS)-G12Di-1*	Ras	Cancer
(RS)-G12Di-1 is a selective, covalent inhibitor of *K-Ras-G12D* .

*KRAS G12C inhibitor 62*	Ras	Cancer
KRAS G12C inhibitor 62 is a KRAS G12C inhibitor. KRAS G12C inhibitor 62 has the potential for the research of KRAS G12C-mediated cancer (extracted from patent WO2021121367A1) .

*Kras4B G12D-IN-1*	Ras	Cancer
Kras4B G12D-IN-1 is a Kras4B G12D inhibitor with anticancer effects. Kras4B G12D-IN-1 decreases Kras protein expression in mouse embryonic fibroblasts (MEF) expressing Kras4B G12D (WO2016179558A1, Comp 994566) .

*K-Ras G12C-IN-1*	Ras	Cancer
K-Ras G12C-IN-1 is a novel and irreversible inhibitor of mutant K-ras G12C extracted from patent WO 2014152588 A1.

*KRAS G12C inhibitor 63*	Ras Apoptosis	Cancer
KRAS G12C inhibitor 63 (K45) is a KRAS G12C inhibitor. KRAS G12C inhibitor 63 can induce Apoptosis. KRAS G12C inhibitor 63 has antitumor activity .

*KRAS G12C inhibitor 57*	Ras	Cancer
KRAS G12C inhibitor 57 (Compound 50) is a potent, selective, covalent and orally active KRAS G12C inhibitor with an IC₅₀ of 0.21 μM in KRAS G12C/SOS1 binding assay. KRAS G12C inhibitor 57 induces cancer cell apoptosis .

*KRAS G12C inhibitor 39*	Ras	Cancer
KRAS G12C inhibitor 39 is a potent inhibitor of KRAS G12C. KRas is a highly attractable target of the pharmaceutical industry for cancer research. KRAS G12C inhibitor 39 has the potential for the research of KRAS G12C-mediated cancer (extracted from patent WO2019099524A1, compound 494) .

*KRAS G12C inhibitor 35*	Ras	Cancer
KRAS G12C inhibitor 35 is a potent inhibitor of KRAS G12C. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12C inhibitor 35 has the potential for the research of KRAS G12C-mediated cancer (extracted from patent CN112920183A, compound 3) .

*KRAS G12D inhibitor 19*	Others	Cancer
KRAS G12D inhibitor 19 (Compound 7) is a KRAS G12D inhibitor. KRAS G12D inhibitor 19 can be used for the research of cancer .

*KRAS G12D inhibitor 20*	Ras	Cancer
KRAS G12D inhibitor 20 (Compound 14) is a selective G12D KRAS inhibitor. KRAS G12D inhibitor 20 has antitumor activity .

*KRAS G12D inhibitor 1*	Ras	Cancer
KRAS G12D inhibitor 1 (example 243) is a KRAS G12D inhibitor, with an IC₅₀ of 0.8 nM for KRAS G12D-mediated ERK phosphorylation . KRAS G12D inhibitor 1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

*KRAS G12C inhibitor 41*	Ras	Cancer
KRAS G12C inhibitor 41 is a potent inhibitor of KRAS G12C. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12C inhibitor 41 has the potential for the research of KRAS G12C-mediated cancer (extracted from patent WO2021129824A1, compound 121) .

*KRAS G12D inhibitor 11*	Ras	Cancer
KRAS G12D inhibitor 11 is a potent inhibitor of KRAS G12D. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12D inhibitor 11 has the potential for the research of KRAS G12D-mediated cancer (extracted from patent WO2021108683A1, compound 52) .

*KRAS G12C inhibitor 40*	Ras	Cancer
KRAS G12C inhibitor 40 is a potent inhibitor of KRAS G12C. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12C inhibitor 40 has the potential for the research of KRAS G12C-mediated cancer (extracted from patent WO2021129824A1, compound 70) .

*KRAS G12D inhibitor 12*	Ras	Cancer
KRAS G12D inhibitor 12 is a potent inhibitor of KRAS G12D. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12D inhibitor 12 has the potential for the research of KRAS G12D-mediated cancer (extracted from patent WO2021108683A1, compound 134) .

*KRAS G12D inhibitor 9*	Ras	Cancer
KRAS G12D inhibitor 9 is a potent inhibitor of KRAS G12D. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12D inhibitor 9 has the potential for the research of KRAS G12D-mediated cancer (extracted from patent WO2021108683A1, compound 20) .

*KRAS G12D inhibitor 10*	Ras	Cancer
KRAS G12D inhibitor 10 is a potent inhibitor of KRAS G12D. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12D inhibitor 10 has the potential for the research of KRAS G12D-mediated cancer (extracted from patent WO2021108683A1, compound 34) .

*KRAS G12D inhibitor 13*	Ras	Cancer
KRAS G12D inhibitor 13 is a potent inhibitor of KRAS G12D. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12D inhibitor 13 has the potential for the research of KRAS G12D-mediated cancer (extracted from patent WO2021108683A1, compound 142) .

*KRAS G12C inhibitor 37*	Ras	Cancer
KRAS G12C inhibitor 37 is a potent inhibitor of KRAS G12C. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12C inhibitor 37 has the potential for the research of KRAS G12C-mediated cancer (extracted from patent WO2018143315A1, compound 65) .

*KRAS G12C inhibitor 38*	Ras	Cancer
KRAS G12C inhibitor 38 is a potent inhibitor of KRAS G12C. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12C inhibitor 38 has the potential for the research of KRAS G12C-mediated cancer (extracted from patent WO2021129820A1, compound 171) .

*KRAS G12C inhibitor 42*	Ras	Cancer
KRAS G12C inhibitor 42 is a potent inhibitor of KRAS G12C. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12C inhibitor 42 has the potential for the research of KRAS G12C-mediated cancer (extracted from patent WO2020146613A1, compound 10) .

*KRAS G12D inhibitor 8*	Ras	Cancer
KRAS G12D inhibitor 8 is a potent inhibitor of KRAS G12D. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12D inhibitor 8 has the potential for the research of KRAS G12D-mediated cancer (extracted from patent WO2021107160A1, compound 2) .

YFLLRNP	Protease Activated Receptor (PAR)	Others
YFLLRNP is a biological active peptide. (a partial agonist of PAR-1. YFLLRNP selectively active G12/13 signaling pathway without activating Gq or Gi pathways at low concentrations. YFLLRNP (60 μM))

*KRAS G12D inhibitor 16*	Ras	Cancer
KRAS G12D inhibitor 16 is a KRAS G12D inhibitor. KRAS G12D inhibitor 16 has inhibitory activity against KRAS G12D and KRAS G12D mutation with IC₅₀ value of 0.7 nM and 0.35 μM, respectively. KRAS G12D inhibitor 16 can be used for the research of many malignant tumor, such as pancreatic ductal adenocarcinomas (PDAC), colon and rectal carcinomas (CRC), non-small cell lung carcinomas (NSCLC) .

*KRAS G12C inhibitor 67*	Ras	Cancer
KRAS G12C inhibitor 67 (example 35) is a KRAS G12C inhibitor that selectively inhibits the growth of many KRAS G12C mutant tumor cell lines .

*KRAS G12C inhibitor 55*	Ras	Cancer
KRAS G12C inhibitor 55 (Compound 1) is a KRAS G12C inhibitor .

*KRAS G12C inhibitor 53*	Ras	Cancer
KRAS G12C inhibitor 53 (Compound 1) is a KRAS G12C inhibitor .

*KRAS G12C inhibitor 51*	Ras	Cancer
KRAS G12C inhibitor 51 (example 1) is a KRAS G12C inhibitor .

*KRAS G12C inhibitor 54*	Ras	Cancer
KRAS G12C inhibitor 54 (Compound 1) is a KRAS G12C inhibitor .

*KRAS G12C inhibitor 52*	Ras	Cancer
KRAS G12C inhibitor 52 (Compound 7) is a KRAS G12C inhibitor .

*KRAS G12C inhibitor 28*	Ras	Cancer
KRAS G12C inhibitor 28 is a KRAS G12C inhibitor with an IC₅₀ of 57 nM. KRAS G12C inhibitor 28 has antitumor effects (WO2021113595A1; Example 1) .

*KRAS G12D inhibitor 24*	Ras	Cancer
KRAS G12D inhibitor 24 (compound 103) is a potent inhibitor of KRAS G12D, with the IC₅₀ of 0.004 μM. KRAS G12D inhibitor 24 has oral bioactivity .

*KRAS G12C inhibitor 68*	Ras	Cancer
KRAS G12C inhibitor 68 (compound I-063) is a KRAS G12C inhibitor with an IC₅₀ of 7 nM. KRAS G12C inhibitor 68 has anti-tumor activity .

*KRAS G12C inhibitor 25*	Ras	Cancer
KRAS G12C inhibitor 25 is a KRAS G12C inhibitor. KRAS G12C inhibitor 25 inhibits SOSl-assisted GDP/GTP exchanging activity of KRAS-G12C mutant (IC₅₀=0.48 nM). From WO2021216770A1 compound 3 .

*PROTAC KRAS G12C degrader-3*	Ras	Cancer
PROTAC KRAS G12C degrader-3 (Comp 283) is a potent KRAS G12C degrader for cancer research .

*KRAS G12C inhibitor 23*	Ras	Cancer
KRAS G12C inhibitor 23 is a KRAS G12C inhibitor. KRAS G12C inhibitor 23 inhibits H358 cells with an IC₅₀ of 491 nM (WO2021218939A1, compound 1) .

*KRAS G12C inhibitor 45*	Ras	Cancer
KRAS G12C inhibitor 45 (compound 78) is a potent KRAS G12C inhibitor .

Cat. No.	Product Name	Target	Research Area

HY-P2360

*G12* Ras 5-17	Peptides	Others
G12 (Ras 5-17) is a wild-type Ras peptide consisted of amino acids 5-17 (KLVVVGAGGVGKS). G12 can be used as a control of mutant Ras peptides studies (such V12) .

HY-P10365

VPM-p15	Peptides	Others
Vmm-p15 is a peptide agonist optimized for the adhesion G protein-coupled receptor GPR64 (also known as ADGRG2 or HE6). The affinity of VPM-p15 with GPR64 is significantly higher than that of the original p15 peptide. The cAMP level induced by VMM-P15 increased significantly, activated GPR64, and triggered downstream Gs, Gq, and G12/13 signaling. VPM-p15 can be used to study the activation mechanism of adherent GPCR family members .

HY-P2265A

SAH-SOS1A TFA	Ras	Cancer
SAH-SOS1A TFA is a peptide-based SOS1/KRAS protein interaction inhibitor. SAH-SOS1A TFA binds to wild-type and mutant KRAS (G12D, G12V, G12C, G12S, and Q61H) with nanomolar affinity (EC₅₀=106-175 nM). SAH-SOS1A TFA directly and independently blocks nucleotide association. SAH-SOS1A TFA impairs KRAS-driven cancer cell viability and exerts its effects by on-mechanism blockade of the ERK-MAPK phosphosignaling cascade downstream of KRAS .

HY-P2360A

G12 TFA Ras 5-17 TFA	Peptides	Others
G12 (Ras 5-17) TFA is a wild-type Ras peptide consisted of amino acids 5-17 (KLVVVGAGGVGKS). G12 TFA can be used as a control of mutant Ras peptides studies (such V12) .

HY-P5192

*KRAS G12D(8-16)*	Peptides	Cancer
KRAS G12D 8-16 is a mutant KRAS G12D 8-16 peptide .

HY-P5358

YFLLRNP	Protease Activated Receptor (PAR)	Others
YFLLRNP is a biological active peptide. (a partial agonist of PAR-1. YFLLRNP selectively active G12/13 signaling pathway without activating Gq or Gi pathways at low concentrations. YFLLRNP (60 μM))

HY-P2265

SAH-SOS1A	Ras	Cancer
SAH-SOS1A is a peptide-based SOS1/KRAS protein interaction inhibitor. SAH-SOS1A binds to wild-type and mutant KRAS (G12D, G12V, G12C, G12S, and Q61H) with nanomolar affinity (EC₅₀=106-175 nM), directly and independently blocks nucleotide association, impairs KRAS-driven cancer cell viability, and exerts its effects by on-mechanism blockade of the ERK-MAPK phosphosignaling cascade downstream of KRAS .

HY-103544

[D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P	JNK Interleukin Related Bombesin Receptor	Inflammation/Immunology Cancer
[D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P, a Substance P derivative, is a biased agonist toward neuropeptide and chemokine receptors. [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P activates *G12. [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P binds to IL-8* and GRP receptors. [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P inhibits ERK-2 activation, activates JNK activity. [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P stimulates an increase in neutrophil migration and Ca ²⁺ mobilization. [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P is also a bombesin antagonist, and inhibits the growth of small cell lung cancer

HY-P3488

GADGVGKSA	Peptides	Inflammation/Immunology Cancer
GADGVGKSA is a mutant *KRAS G12D 9mer* peptide. GADGVGKSA can be used as an immunogenic neoantigen for cancer immunotherapy research .

HY-P3486

GADGVGKSAL	Peptides	Inflammation/Immunology Cancer
GADGVGKSAL is a mutant *KRAS G12D 10mer* peptide. GADGVGKSAL can be used as an immunogenic neoantigen for cancer immunotherapy research .

HY-P3485

GAGGVGKSAL	Peptides	Cancer
GAGGVGKSAL is a wild-type *KRAS G12D 10mer* peptide. GAGGVGKSAL can be used as an immunogenic neoantigen for cancer immunotherapy research .

HY-P3487

GAGGVGKSA	Peptides	Inflammation/Immunology Cancer
GAGGVGKSA is a wild type *KRAS G12D 9mer* peptide. GAGGVGKSA can be used as an immunogenic neoantigen for cancer immunotherapy research .

Cat. No.	Product Name	Target	Research Area

HY-P99611

Faralimomab 64G12	IFNAR	Inflammation/Immunology
Faralimomab (64G12) is an immunomodulator, and a murine anti-IFNA1 IgG1 mAb .

HY-P990169

Anti-Mouse/Human phosphorylated PD-1/CD279 Antibody (407.6G12)	Inhibitory Antibodies	Others
Anti-Mouse/Human phosphorylated PD-1/CD279 Antibody (407.6G12) is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to mouse/human phosphorylated PD-1/CD279.

HY-P990633

NC-318 (5G-12) 5G-12	Inhibitory Antibodies	Inflammation/Immunology

Species:	Human (26) Mouse (1)
Tag:	His (27) Avi (21)
Source:	HEK293 (22) E. coli (5)

Cat. No.	Compare	Product Name	Species	Source

HY-P70153

	*KRAS Protein, Human (G12S, His)* rHuKRAS-G12S, His; Ki-Ras; c-K-ras; KRAS2; RASK2; CFC2	Human	E. coli
	KRAS protein is a key Ras family member that binds GDP/GTP and has intrinsic GTPase activity. Its critical role in regulating cell proliferation emphasizes its importance in cellular processes. KRAS Protein, Human (G12S, His) is the recombinant human-derived KRAS, expressed by E. coli , with N-6*His labeled tag. ,

HY-P70232

	*Kras4B Protein, Human (G12C, His)* rHuGTPase Kras4B-G12C, His; Ki-Ras; c-K-ras; KRAS2; RASK2; CFC2	Human	E. coli
	The Kras4B protein interacts specifically with GPR31, dependent on farnesylation. This binding suggests a regulatory role for Kras4B in association with GPR31, emphasizing the importance of the farnesylation process. Comprehensive exploration into the molecular details of this interaction is crucial to understand the precise mechanisms and functional implications in cellular processes or signaling pathways. Kras4B Protein, Human (G12C, His) is the recombinant human-derived Kras4B protein, expressed by E. coli , with N-6*His labeled tag and G12C, , , , mutation. The total length of Kras4B Protein, Human (G12C, His) is 169 a.a., with molecular weight of ~23.0 kDa.

HY-P70234

	*Kras4B Protein, Human (G12V, His)* rHuGTPase Kras4B-G12V, His; Ki-Ras; c-K-ras; KRAS2; RASK2; CFC2	Human	E. coli
	The Kras4B protein interacts specifically with GPR31, dependent on farnesylation. This binding suggests a regulatory role for Kras4B in association with GPR31, emphasizing the importance of the farnesylation process. Comprehensive exploration into the molecular details of this interaction is crucial to understand the precise mechanisms and functional implications in cellular processes or signaling pathways. Kras4B Protein, Human (G12V, His) is the recombinant human-derived Kras4B protein, expressed by E. coli , with N-6*His labeled tag. The total length of Kras4B Protein, Human (G12V, His) is 150 a.a., with molecular weight of ~24.0 kDa.

HY-P7804

	*KRAS Protein, Human (G12C, His)* Ki-Ras; c-K-ras; KRAS2; RASK2	Human	E. coli
	KRAS Protein, Human (G12C, His) expresses in E. coli with a His tag at the N-terminus. KRAS G12C is an oncogenic driver mutation in multiple cancer types.

HY-P7805

	*KRAS Protein, Human (G12V, His)* Ki-Ras; c-K-ras; KRAS2; RASK2; KRAS4B; KRAS4B; K-Ras4B	Human	E. coli
	KRAS Protein, a pivotal Ras family member, binds GDP/GTP and possesses intrinsic GTPase activity. Its crucial role in regulating cell proliferation emphasizes its significance in cellular processes. Notably, KRAS plays a prominent role in promoting oncogenic events, particularly in colorectal cancer (CRC), inducing transcriptional silencing of tumor suppressor genes (TSGs) in a ZNF304-dependent manner. This multifaceted functionality underscores KRAS as a key player in cellular dynamics, relevant in both normal and pathological processes. KRAS Protein, Human (G12V, His) is the recombinant human-derived KRAS protein, expressed by E. coli , with N-6*His labeled tag and G12V mutation. The total length of KRAS Protein, Human (G12V, His) is 184 a.a., with molecular weight of 25-30 kDa, observed by reducing SDS-PAGE.

HY-P77783

	*HLA-A1101 KRAS G12D Protein, Human (HEK293, His-Avi)** MHC; KRAS; K-Ras 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase Kras; KI-RAS; RALD	Human	HEK293
	HLA-A1101as is a key MHCI molecule that presents viral and tumor-derived peptides that direct T cell immune responses against infected or transformed cells. It collaborates with B2M to showcase a diverse peptide library. HLA-A1101 KRAS G12D Protein, Human (HEK293, His-Avi) is a recombinant protein dimer complex containing HLA-A1101 and B2M/Beta-2-microglobulin Protein, expressed by HEK293* , with C-Avi, C-His labeled tag and VVVGADGVGK peptide. HLA-A*1101 KRAS G12D Protein, Human (HEK293, His-Avi), has molecular weight of 51-60 kDa.

HY-P77786

	*HLA-A1101 KRAS G12V Complex Protein, Human (HEK293, His-Avi)** MHC; KRAS; K-Ras 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase Kras; KI-RAS; RALD	Human	HEK293
	HLA-A1101as is a key MHCI molecule that presents viral and tumor-derived peptides that direct T cell immune responses against infected or transformed cells. It collaborates with B2M to showcase a diverse peptide library. HLA-A1101 KRAS G12V Complex Protein, Human (HEK293, His-Avi) is a recombinant protein dimer complex containing HLA-A1101 and B2M/Beta-2-microglobulin Protein, expressed by HEK293* , with C-Avi, C-His labeled tag and VVGAVGVGK peptide. HLA-A*1101 KRAS G12V Complex Protein, Human (HEK293, His-Avi), has molecular weight of 42-46 kDa.

HY-P77144

	PLA2G12B Protein, Mouse (HEK293, His) Group XIIB phospholipase A2-like protein	Mouse	HEK293
	PLA2G12B Protein, Mouse (HEK293, His) is the recombinant mouse-derived PLA2G12B protein, expressed by HEK293 , with C-His labeled tag. The total length of PLA2G12B Protein, Mouse (HEK293, His) is 176 a.a., with molecular weight of ~24 kDa.

HY-P77781

	*HLA-A0301 KRAS G12V Complex Protein, Human (HEK293, His-Avi)** MHC; KRAS; K-Ras 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase Kras; KI-RAS; RALD	Human	HEK293
	HLA-A0301 collaborates with B2M to present viral and tumor peptides that direct CD8-positive T cells to respond against infected or transformed cells. It can also present self-peptides to avoid self-reaction. HLA-A0301 KRAS G12V Complex Protein, Human (HEK293, His-Avi) is a recombinant protein dimer complex containing HLA-A0301 and B2M/Beta-2-microglobulin Protein, expressed by HEK293* , with C-Avi, C-His labeled tag and VVGAVGVGK peptide. HLA-A*0301 KRAS G12V Complex Protein, Human (HEK293, His-Avi), has molecular weight of 55-60 kDa.

HY-P77785

	*HLA-A1101 KRAS G12D Tetramer Protein, Human (HEK293, His-Avi)** MHC; KRAS; K-Ras 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase Kras; KI-RAS; RALD	Human	HEK293
	HLA-A1101as is a key MHCI molecule that presents viral and tumor-derived peptides that direct T cell immune responses against infected or transformed cells. It collaborates with B2M to showcase a diverse peptide library. HLA-A1101 KRAS G12D Tetramer Protein, Human (HEK293, His-Avi) is a recombinant protein dimer complex containing HLA-A1101 and B2M/Beta-2-microglobulin Protein, expressed by HEK293* , with C-Avi, C-His labeled tag and VVVGADGVGK peptide. HLA-A*1101 KRAS G12D Tetramer Protein, Human (HEK293, His-Avi), has molecular weight of 260-265 kDa.

HY-P77782

	*HLA-A0301 KRAS G12V Complex Tetramer Protein, Human (HEK293, His-Avi)** MHC; KRAS; K-Ras 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase Kras; KI-RAS; RALD	Human	HEK293
	HLA-A0301 collaborates with B2M to present viral and tumor peptides that direct CD8-positive T cells to respond against infected or transformed cells. It can also present self-peptides to avoid self-reaction. HLA-A0301 KRAS G12V Complex Tetramer Protein, Human (HEK293, His-Avi) is a recombinant protein dimer complex containing HLA-A0301 and B2M/Beta-2-microglobulin Protein, expressed by HEK293* , with C-Avi, C-His labeled tag and VVGAVGVGK peptide. HLA-A*0301 KRAS G12V Complex Tetramer Protein, Human (HEK293, His-Avi), has molecular weight of 260-265 kDa.

HY-P77784

	*HLA-A1101 KRAS G12D Complex Protein, Human (Biotinylated, VVVGADGVGK, HEK293, His-Avi)** MHC; KRAS; K-Ras 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase Kras; KI-RAS; RALD	Human	HEK293
	HLA-A1101as, a pivotal MHCI molecule, presents viral and tumor-derived peptides, guiding T cell immune responses against infected or transformed cells. Collaborating with B2M, it displays a diverse peptide repertoire. Both the presented peptide and MHCI contribute to antigen recognition specificity. HLA-A1101 typically presents 8 to 13 amino acid intracellular peptides, binding different peptides with allele-specific motifs. It plays a crucial role in controlling infections, presenting immunodominant epitopes from HIV-1, EBV, HBV, and contributing to the immune response against SARS-CoV-2. HLA-A1101 KRAS G12D Complex Protein, Human (Biotinylated, VVVGADGVGK, HEK293, His-Avi) is a recombinant protein dimer complex containing HLA-A1101 and B2M/Beta-2-microglobulin Protein, expressed by HEK293 , with C-Avi, C-His labeled tag and VVVGADGVGK peptide. HLA-A*1101 KRAS G12D Complex Protein, Human (Biotinylated, VVVGADGVGK, HEK293, His-Avi), has molecular weight of 51-60 kDa.

HY-P77787

	*HLA-A1101 KRAS G12V Complex Protein, Human (Biotinylated, VVGAVGVGK, HEK293, His-Avi)** MHC; KRAS; K-Ras 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase Kras; KI-RAS; RALD	Human	HEK293
	HLA-A1101as, a pivotal MHCI molecule, presents viral and tumor-derived peptides, guiding T cell immune responses against infected or transformed cells. Collaborating with B2M, it displays a diverse peptide repertoire. Both the presented peptide and MHCI contribute to antigen recognition specificity. HLA-A1101 typically presents 8 to 13 amino acid intracellular peptides, binding different peptides with allele-specific motifs. It plays a crucial role in controlling infections, presenting immunodominant epitopes from HIV-1, EBV, HBV, and contributing to the immune response against SARS-CoV-2. HLA-A1101 KRAS G12V Complex Protein, Human (Biotinylated, VVGAVGVGK, HEK293, His-Avi) is a recombinant protein dimer complex containing HLA-A1101 and B2M/Beta-2-microglobulin Protein, expressed by HEK293 , with C-Avi, C-His labeled tag and VVGAVGVGK peptide. HLA-A*1101 KRAS G12V Complex Protein, Human (Biotinylated, VVGAVGVGK, HEK293, His-Avi), has molecular weight of 51-60 kDa.

HY-P77788

	*HLA-A1101 KRAS G12V Complex Tetramer Protein, Human (HEK293, His-Avi)** MHC; KRAS; K-Ras 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase Kras; KI-RAS; RALD	Human	HEK293
	HLA-A1101as is a key MHCI molecule that presents viral and tumor-derived peptides that direct T cell immune responses against infected or transformed cells. It collaborates with B2M to showcase a diverse peptide library. HLA-A1101 KRAS G12V Complex Tetramer Protein, Human (HEK293, His-Avi) is a recombinant protein dimer complex containing HLA-A1101 and B2M/Beta-2-microglobulin Protein, expressed by HEK293* , with C-Avi, C-His labeled tag and VVGAVGVGK peptide. HLA-A*1101 KRAS G12V Complex Tetramer Protein, Human (HEK293, His-Avi), has molecular weight of 260-265 kDa.

HY-P700919

	*HLA-A1101 KRAS G12A Complex Protein, Human (Biotinylated, VVVGAAGVGK, HEK293, His-Avi)** MHC; KRAS; K-Ras 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase Kras; KI-RAS; RALD	Human	HEK293
	HLA-A1101as, a pivotal MHCI molecule, presents viral and tumor-derived peptides, guiding T cell immune responses against infected or transformed cells. Collaborating with B2M, it displays a diverse peptide repertoire. Both the presented peptide and MHCI contribute to antigen recognition specificity. HLA-A1101 typically presents 8 to 13 amino acid intracellular peptides, binding different peptides with allele-specific motifs. It plays a crucial role in controlling infections, presenting immunodominant epitopes from HIV-1, EBV, HBV, and contributing to the immune response against SARS-CoV-2. HLA-A1101 KRAS G12A Complex Protein, Human (Biotinylated, VVVGAAGVGK, HEK293, His-Avi) is a recombinant protein dimer complex containing HLA-A1101 and B2M/Beta-2-microglobulin Protein, expressed by HEK293 , with C-Avi, C-His labeled tag and VVVGAAGVGK peptide. HLA-A*1101 KRAS G12A Complex Protein, Human (Biotinylated, VVVGAAGVGK, HEK293, His-Avi), has molecular weight of 52-62 kDa.

HY-P700920

	*HLA-A1101 KRAS G12A Complex Protein, Human (VVVGAAGVGK, HEK293, His-Avi)** MHC; KRAS; K-Ras 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase Kras; KI-RAS; RALD	Human	HEK293
	HLA-A1101as is a key MHCI molecule that presents viral and tumor-derived peptides that direct T cell immune responses against infected or transformed cells. It collaborates with B2M to showcase a diverse peptide library. HLA-A1101 KRAS G12A Complex Protein, Human (VVVGAAGVGK, HEK293, His-Avi) is a recombinant protein dimer complex containing HLA-A1101 and B2M/Beta-2-microglobulin Protein, expressed by HEK293* , with C-Avi, C-His labeled tag and VVVGAAGVGK peptide. HLA-A*1101 KRAS G12A Complex Protein, Human (VVVGAAGVGK, HEK293, His-Avi), has molecular weight of 52-62 kDa.

HY-P700921

	*HLA-A1101 KRAS G12C Complex Protein, Human (Biotinylated, VVVGACGVGK, HEK293, His-Avi)** MHC; KRAS; K-Ras 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase Kras; KI-RAS; RALD	Human	HEK293
	HLA-A1101as, a pivotal MHCI molecule, presents viral and tumor-derived peptides, guiding T cell immune responses against infected or transformed cells. Collaborating with B2M, it displays a diverse peptide repertoire. Both the presented peptide and MHCI contribute to antigen recognition specificity. HLA-A1101 typically presents 8 to 13 amino acid intracellular peptides, binding different peptides with allele-specific motifs. It plays a crucial role in controlling infections, presenting immunodominant epitopes from HIV-1, EBV, HBV, and contributing to the immune response against SARS-CoV-2. HLA-A1101 KRAS G12C Complex Protein, Human (Biotinylated, VVVGACGVGK, HEK293, His-Avi) is a recombinant protein dimer complex containing HLA-A1101 and B2M/Beta-2-microglobulin Protein, expressed by HEK293 , with C-Avi, C-His labeled tag and VVVGACGVGK peptide. HLA-A*1101 KRAS G12C Complex Protein, Human (Biotinylated, VVVGACGVGK, HEK293, His-Avi), has molecular weight of 53-63 kDa.

HY-P700922

	*HLA-A1101 KRAS G12C Complex Protein, Human (VVVGACGVGK, HEK293, His-Avi)** MHC; KRAS; K-Ras 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase Kras; KI-RAS; RALD	Human	HEK293
	HLA-A1101as is a key MHCI molecule that presents viral and tumor-derived peptides that direct T cell immune responses against infected or transformed cells. It collaborates with B2M to showcase a diverse peptide library. HLA-A1101 KRAS G12C Complex Protein, Human (VVVGACGVGK, HEK293, His-Avi) is a recombinant protein dimer complex containing HLA-A1101 and B2M/Beta-2-microglobulin Protein, expressed by HEK293* , with C-Avi, C-His labeled tag and VVVGACGVGK peptide. HLA-A*1101 KRAS G12C Complex Protein, Human (VVVGACGVGK, HEK293, His-Avi), has molecular weight of 53-63 kDa.

HY-P700923

	*HLA-A1101 KRAS G12R Complex Protein, Human (Biotinylated, VVVGARGVGK, HEK293, His-Avi)** MHC; KRAS; K-Ras 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase Kras; KI-RAS; RALD	Human	HEK293
	HLA-A1101as, a pivotal MHCI molecule, presents viral and tumor-derived peptides, guiding T cell immune responses against infected or transformed cells. Collaborating with B2M, it displays a diverse peptide repertoire. Both the presented peptide and MHCI contribute to antigen recognition specificity. HLA-A1101 typically presents 8 to 13 amino acid intracellular peptides, binding different peptides with allele-specific motifs. It plays a crucial role in controlling infections, presenting immunodominant epitopes from HIV-1, EBV, HBV, and contributing to the immune response against SARS-CoV-2. HLA-A1101 KRAS G12R Complex Protein, Human (Biotinylated, VVVGARGVGK, HEK293, His-Avi) is a recombinant protein dimer complex containing HLA-A1101 and B2M/Beta-2-microglobulin Protein, expressed by HEK293 , with C-Avi, C-His labeled tag and VVVGARGVGK peptide. HLA-A*1101 KRAS G12R Complex Protein, Human (Biotinylated, VVVGARGVGK, HEK293, His-Avi), has molecular weight of 53-63 kDa.

HY-P700924

	*HLA-A1101 KRAS G12R Complex Protein, Human (VVVGAAGVGK, HEK293, His-Avi)** MHC; KRAS; K-Ras 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase Kras; KI-RAS; RALD	Human	HEK293
	HLA-A1101as is a key MHCI molecule that presents viral and tumor-derived peptides that direct T cell immune responses against infected or transformed cells. It collaborates with B2M to showcase a diverse peptide library. HLA-A1101 KRAS G12R Complex Protein, Human (VVVGAAGVGK, HEK293, His-Avi) is a recombinant protein dimer complex containing HLA-A1101 and B2M/Beta-2-microglobulin Protein, expressed by HEK293* , with C-Avi, C-His labeled tag and VVVGARGVGK peptide. HLA-A*1101 KRAS G12R Complex Protein, Human (VVVGAAGVGK, HEK293, His-Avi), has molecular weight of 53-63 kDa.

HY-P700925

	*HLA-A1101 KRAS G12S Complex Protein, Human (Biotinylated, VVVGASGVGK, HEK293, His-Avi)** MHC; KRAS; K-Ras 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase Kras; KI-RAS; RALD	Human	HEK293
	HLA-A1101as, a pivotal MHCI molecule, presents viral and tumor-derived peptides, guiding T cell immune responses against infected or transformed cells. Collaborating with B2M, it displays a diverse peptide repertoire. Both the presented peptide and MHCI contribute to antigen recognition specificity. HLA-A1101 typically presents 8 to 13 amino acid intracellular peptides, binding different peptides with allele-specific motifs. It plays a crucial role in controlling infections, presenting immunodominant epitopes from HIV-1, EBV, HBV, and contributing to the immune response against SARS-CoV-2. HLA-A1101 KRAS G12S Complex Protein, Human (Biotinylated, VVVGASGVGK, HEK293, His-Avi) is a recombinant protein dimer complex containing HLA-A1101 and B2M/Beta-2-microglobulin Protein, expressed by HEK293 , with C-Avi, C-His labeled tag and VVVGASGVGK peptide. HLA-A*1101 KRAS G12S Complex Protein, Human (Biotinylated, VVVGASGVGK, HEK293, His-Avi), has molecular weight of 53-63 kDa.

HY-P700926

	*HLA-A1101 KRAS G12S Complex Protein, Human (VVVGASGVGK, HEK293, His-Avi)** MHC; KRAS; K-Ras 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase Kras; KI-RAS; RALD	Human	HEK293
	HLA-A1101as is a key MHCI molecule that presents viral and tumor-derived peptides that direct T cell immune responses against infected or transformed cells. It collaborates with B2M to showcase a diverse peptide library. HLA-A1101 KRAS G12S Complex Protein, Human (VVVGASGVGK, HEK293, His-Avi) is a recombinant protein dimer complex containing HLA-A1101 and B2M/Beta-2-microglobulin Protein, expressed by HEK293* , with C-Avi, C-His labeled tag and VVVGASGVGK peptide. HLA-A*1101 KRAS G12S Complex Protein, Human (VVVGASGVGK, HEK293, His-Avi), has molecular weight of 53-63 kDa.

HY-P700927

	*HLA-A0301 KRAS G12V Complex Protein, Human (Biotinylated, VVGAVGVGK, HEK293, His-Avi)** MHC; KRAS; K-Ras 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase Kras; KI-RAS; RALD	Human	HEK293
	HLA-A0301 collaborates with B2M to present viral and tumor peptides, guiding CD8-positive T cell responses against infected or transformed cells. It can also present self-peptides, avoiding autoreactivity. The antigen recognition specificity involves the peptide and MHC residues, with HLA-A0301 presenting 8 to 13 amino acid peptides, characterized by allele-specific binding motifs. Specific alleles, like A01:01 and A03:01, present a distinct repertoire of peptides, including viral and tumor epitopes. HLA-A0301 KRAS G12V Complex Protein, Human (Biotinylated, VVGAVGVGK, HEK293, His-Avi) is a recombinant protein dimer complex containing HLA-A0301 and B2M/Beta-2-microglobulin Protein, expressed by HEK293 , with C-Avi, C-His labeled tag and VVGAVGVGK peptide. HLA-A*0301 KRAS G12V Complex Protein, Human (Biotinylated, VVGAVGVGK, HEK293, His-Avi), has molecular weight of 52-60 kDa.

HY-P700928

	*HLA-A0301 KRAS G12V Complex Protein, Human (VVGAVGVGK, HEK293, His-Avi)** MHC; KRAS; K-Ras 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase Kras; KI-RAS; RALD	Human	HEK293
	HLA-A1101as is a key MHCI molecule that presents viral and tumor-derived peptides that direct T cell immune responses against infected or transformed cells. It collaborates with B2M to showcase a diverse peptide library. HLA-A0301 KRAS G12V Complex Protein, Human (VVGAVGVGK, HEK293, His-Avi) is a recombinant protein dimer complex containing HLA-A1101 and B2M/Beta-2-microglobulin Protein, expressed by HEK293* , with C-Avi, C-His labeled tag and VVGAVGVGK peptide. HLA-A*0301 KRAS G12V Complex Protein, Human (VVGAVGVGK, HEK293, His-Avi), has molecular weight of 56-65 kDa.

HY-P701086

	*HLA-C0304 KRAS G12D Complex Protein, Human (Biotinylated, GADGVGKSAL, HEK293, His-Avi)** MHC; KRAS; K-Ras 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase Kras; KI-RAS; RALD	Human	HEK293
	The HLA-C0304 KRAS G12D Complex, a major histocompatibility complex class I (MHCI) molecule, plays crucial roles in reproduction and antiviral immunity. Teaming up with B2M, it presents self and viral peptides, acting as a dominant ligand for inhibitory and activating killer immunoglobulin receptors (KIRs) on NK cells. In allogeneic contexts, it facilitates trophoblast interactions with NK cells, crucial for placental development. During viral infections, HLA-C0304 may disrupt KIR-mediated inhibition and promote infected cell lysis. In adaptive immunity, it presents viral peptides to CD8-positive T cells, contributing to antigen-specific T cell responses in chronic viral infections. HLA-C0304's fine specificity for antigen recognition and its role in immune surveillance stem from its ability to recognize diverse peptides and specific MHC residues. HLA-C0304 KRAS G12D Complex Protein, Human (Biotinylated, GADGVGKSAL, HEK293, His-Avi) is a recombinant protein dimer complex containing HLA-C0304 and B2M/Beta-2-microglobulin Protein, expressed by HEK293* , with C-Avi, C-His labeled tag and GADGVGKSAL peptide. HLA-C*0304 KRAS G12D Complex Protein, Human (Biotinylated, GADGVGKSAL, HEK293, His-Avi), has molecular weight of 55-65 kDa.

HY-P701087

	*HLA-C0304 KRAS G12D Complex Protein, Human (GADGVGKSAL, HEK293, His-Avi)** MHC; KRAS; K-Ras 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase Kras; KI-RAS; RALD	Human	HEK293
	The HLA-C0304 KRAS G12D complex is a major histocompatibility complex class I (MHCI) molecule that plays a crucial role in reproduction and antiviral immunity. It collaborates with B2M to present self- and viral peptides as primary ligands that inhibit and activate killer immunoglobulin receptors (KIRs) on NK cells. HLA-C0304 KRAS G12D Complex Protein, Human (GADGVGKSAL, HEK293, His-Avi) is a recombinant protein dimer complex containing HLA-C0304 and B2M/Beta-2-microglobulin Protein, expressed by HEK293* , with C-Avi, C-His labeled tag and GADGVGKSAL peptide. HLA-C*0304 KRAS G12D Complex Protein, Human (GADGVGKSAL, HEK293, His-Avi), has molecular weight of 55-65 kDa.

HY-P701088

	*HLA-C0304 KRAS G12D Complex Tetramer Protein, Human (GADGVGKSAL, HEK293, His-Avi)** MHC; KRAS; K-Ras 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase Kras; KI-RAS; RALD	Human	HEK293
	The HLA-C0304 KRAS G12D complex is a major histocompatibility complex class I (MHCI) molecule that plays a crucial role in reproduction and antiviral immunity. It collaborates with B2M to present self- and viral peptides as primary ligands that inhibit and activate killer immunoglobulin receptors (KIRs) on NK cells. HLA-C0304 KRAS G12D Complex Tetramer Protein, Human (GADGVGKSAL, HEK293, His-Avi) is a recombinant protein dimer complex containing HLA-C0304 and B2M/Beta-2-microglobulin Protein, expressed by HEK293* , with C-Avi, C-His labeled tag and GADGVGKSAL peptide. HLA-C*0304 KRAS G12D Complex Tetramer Protein, Human (GADGVGKSAL, HEK293, His-Avi), has molecular weight of 260-265 kDa.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-157029S

KRASG12D-IN-1
KRASG12D-IN-1 (compound 22) is a KRAS ^G12D Inhibitor. KRASG12D-IN-1 has dose-dependent anti-tumor efficacy in the AsPC-1 xenograft mouse models with a tumor growth inhibition .

HY-157031S

KRASG12D-IN-2
KRASG12D-IN-2 (compound 28) is a KRAS ^G12D Inhibitor. KRASG12D-IN-1 has dose-dependent anti-tumor efficacy in the AsPC-1 xenograft mouse models with a tumor growth inhibition .

HY-114277S

Sotorasib-d7
Sotorasib-d₇ (AMG-510-d₇) is a deuterium-labeled Sotorasib (HY-114277). Sotorasib is an orally active covalent inhibitor of KRAS G12C. Sotorasib can lead to the regression of KRAS G12C tumors .

HY-114436S

MRTX-1257-d6
MRTX-1257-d₆ is the deuterium labeled MRTX-1257 (HY-114436). MRTX-1257 is a selective, irreversible, covalent and orally active KRAS G12C inhibitor, with an IC₅₀ of 900 pM for KRAS dependent ERK phosphorylation in H358 cells .

Cat. No.	Product Name		Classification

HY-134811

*KRAS G12D inhibitor 1*		Alkynes
KRAS G12D inhibitor 1 (example 243) is a KRAS G12D inhibitor, with an IC₅₀ of 0.8 nM for KRAS G12D-mediated ERK phosphorylation . KRAS G12D inhibitor 1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-115880A

*KRAS G12D inhibitor 3 TFA*		Alkynes
KRAS G12D inhibitor 3 TFA is a KRAS G12D inhibitor with an IC₅₀ of <500 nM. KRAS G12D inhibitor 3 TFA has antitumor effects (WO2022002102A1; compound 146) . KRAS G12D inhibitor 3 (TFA) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-134813

MRTX1133 10+ Cited Publications		Alkynes
MRTX1133 is a noncovalent, potent, and selective KRAS G12D inhibitor. MRTX1133 optimally fills the switch II pocket and extends three substituents to favorably interact with the protein, resulting in an estimated K_D against KRAS G12D of 0.2 pM. MRTX1133 prevents SOS1-catalyzed nucleotide exchange and/or formation of the KRAS G12D/GTP/RAF1 complex, thereby inhibiting mutant KRAS-dependent signal transduction. MRTX1133 selectively inhibits KRAS G12D mutant, but not KRAS wild-type, tumor cells. MRTX1133 has single digit nanomolar activity in cellular assays and marked in vivo efficacy in tumor models harboring KRAS G12D mutations .

HY-158007

*(RS)-G12Di-1*		Alkynes
(RS)-G12Di-1 is a selective, covalent inhibitor of *K-Ras-G12D* .

HY-158701

*KRAS G12D inhibitor 23*		Alkynes
KRAS G12D inhibitor 23 (compound 46-3) is a potent inhibitor of KRAS G12D, with the IC₅₀ of 0.007 μM. KRAS G12D inhibitor 23 plays an important role in cancer research .

HY-115880

*KRAS G12D inhibitor 3*		Alkynes
KRAS G12D inhibitor 3 is a KRAS G12D inhibitor with an IC₅₀ of <500 nM. KRAS G12D inhibitor 3 has antitumor effects (WO2022002102A1; compound 146) . KRAS G12D inhibitor 3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-147595

*KRAS G12D inhibitor 15*		Alkynes
KRAS G12D inhibitor 15 is a potent inhibitor of KRAS G12D. KRAS G12D inhibitor 15 has the potential for the research of various diseases or disorders, such as cancer or cancer metastasis (extracted from patent WO2022042630A1, compound 243) . KRAS G12D inhibitor 15 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-159652

KRAS inhibitor-31		Alkynes
KRAS inhibitor-31 (compound 33) is a KRAS inhibitor, with K_D (SPR) values of 0.019 nM, 0.019 nM and 0.096 nM for KRas G12D, KRas G12C and KRas G12V, respectively .

HY-159474

KRAS inhibitor-24		Azide
KRAS inhibitor-24 (compound 115c) is a pyridopyrimidine KRAS inhibitor, with an IC₅₀ of < 100 nM for KRas G12V, KRas WT and KRas G12R .

HY-159475

KRAS inhibitor-25		Azide
KRAS inhibitor-25 (compound 151a) is a pyridopyrimidine KRAS inhibitor, with an IC₅₀ of < 100 nM against KRas G12V, KRas WT and KRas G12R .

HY-162446

pan-KRAS-IN-13		Alkynes
pan-KRAS-IN-13 (compound 2) is a potent inhibitor of KRAS, with IC₅₀s of 2.75 nM and 2.89 nM for G12D and G12V, respectively

HY-145962

MRTX-EX185		Alkynes
MRTX-EX185 is a potent inhibitor of GDP-loaded KRAS and *KRAS(G12D), with an IC₅₀* of 90 nM for KRAS(G12D). MRTX-EX185 also binds GDP-loaded HRAS . MRTX-EX185 is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-145962A

MRTX-EX185 formic		Alkynes
MRTX-EX185 formic is a potent inhibitor of GDP-loaded KRAS and *KRAS(G12D), with an IC₅₀* of 90 nM for KRAS(G12D). MRTX-EX185 formic also binds GDP-loaded HRAS . MRTX-EX185 (formic) is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-134654

MRTX849 analog 24		Alkynes
MRTX849 analog 24 is an alkyne-containing click probe analogue of KRAS G12C inhibitor MRTX849, which is used to research MRTX849 function .

HY-159476

KRAS inhibitor-26		Azide
KRAS inhibitor-26 (compound 194a) is a potent KRAS G12V inhibitor (IC₅₀: ≤100 nM). KRAS inhibitor-26 can be used for cancer research .

HY-159473

K-Ras-IN-3		Alkynes
K-Ras-IN-3 (compound 3) is a potent GDP-KRAS G12V inhibitor with an IC₅₀ value of 0.371 nM. K-Ras-IN-3 has the potential for the research of cancer .

HY-157029S

KRASG12D-IN-1		Alkynes
KRASG12D-IN-1 (compound 22) is a KRAS ^G12D Inhibitor. KRASG12D-IN-1 has dose-dependent anti-tumor efficacy in the AsPC-1 xenograft mouse models with a tumor growth inhibition .

HY-157031S

KRASG12D-IN-2		Alkynes
KRASG12D-IN-2 (compound 28) is a KRAS ^G12D Inhibitor. KRASG12D-IN-1 has dose-dependent anti-tumor efficacy in the AsPC-1 xenograft mouse models with a tumor growth inhibition .

HY-128522

ARS-1323-alkyne		Alkynes
ARS-1323-alkyne, a switch-II pocket (S-IIP) inhibitor, is a conformational specific chemical reporter of KRAS ^G12C nucleotide state in living cells . ARS-1323-alkyne is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Cat. No.	Product Name		Classification

HY-RS10617

PLA2G12A Human Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
PLA2G12A Human Pre-designed siRNA Set A contains three designed siRNAs for PLA2G12A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS10618

PLA2G12B Human Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
PLA2G12B Human Pre-designed siRNA Set A contains three designed siRNAs for PLA2G12B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

G 12

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

Natural
Products